| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 18 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 890.4K | $40.16M | - | |
| CEO | 875.0K | $39.46M | - | |
| Other | 740.2K | $33.38M | - | |
| 10% | 245.7K | $11.08M | -281,408 | |
| COO | 215.0K | $9.70M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2025 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sell | 5,000 | $16.31 | $81,533.50 | -0.5% | +17.2% | +138.4% | |
| May 19, 2025 | Kintz Samuel51 | President And CEO | Sell | 5,000 | $16.49 | $82,453.00 | -0.5% | +17.2% | +138.4% | |
| May 7, 2025 | Patel Anish54 | Chief Operating Officer | Sell | 6,667 | $18.39 | $122,578.86 | -0.7% | +5.2% | +120.5% | |
| May 2, 2025 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sell | 7,500 | $20.05 | $150,390.64 | -0.4% | -8.3% | +103.3% | |
| May 2, 2025 | Kintz Samuel51 | President And CEO | Sell | 7,500 | $20.06 | $150,415.36 | -0.4% | -8.3% | +103.3% | |
| Apr 28, 2025 | Hohl Benjamin60 | Chief Financial Officer | Sale+OE | 3,250 | $18.69 | $60,737.55 | -6.6% | +9.3% | +127.3% | |
| Apr 21, 2025 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sell | 5,000 | $16.07 | $80,365.82 | -0.2% | +34.8% | - | |
| Apr 17, 2025 | Kintz Samuel51 | President And CEO | Sell | 5,000 | $16.42 | $82,096.00 | -0.5% | +29.8% | - | |
| Apr 7, 2025 | Patel Anish54 | Chief Operating Officer | Sell | 6,667 | $18.04 | $120,268.73 | -0.7% | +9.6% | +141.5% | |
| Mar 27, 2025 | Hohl Benjamin60 | Chief Financial Officer | Sale+OE | 3,250 | $21.33 | $69,320.88 | -12.4% | -0.0% | +80.5% |